A retrospective study assessing Adverse Events and Serological Responses Following SARS-CoV-2 Vaccination in Individuals With Inflammatory Bowel Disease
Latest Information Update: 23 Dec 2022
At a glance
- Drugs AZD 1222 (Primary) ; Elasomeran (Primary) ; Tozinameran (Primary)
- Indications COVID 2019 infections
- Focus Adverse reactions; Therapeutic Use
Most Recent Events
- 23 Dec 2022 New trial record
- 26 Oct 2022 Results presented at the American College of Gastroenterology Annual Scientific Meeting and Postgraduate Course 2022